检测宫颈癌中肿瘤细胞增殖相关因子的表达

目的: 探讨p16、CyclinD1、PTEN蛋白和DNA异倍体在宫颈癌中的表达意义。 方法: 采用免疫组织化学SP法和流式细胞仪技术检测19例正常宫颈NC、22例CIN,82例浸润性宫颈癌ICC中p16、CyclinD1、PTEN和DNA异倍体数的表达。 结果: p16、CyclinD1、DNA异倍体从NC到CIN再到ICC中逐渐升高,而PTEN逐渐缺失,P<0.05;p16、PTEN、CyclinD1与临床分期、淋巴转移相关,P<0.05;而DNA异倍体与各项参数均不相关(P>0.05)。CyclinD1与p16、DNA异倍体、PTEN,PTEN和DNA异倍体表达相关(P<0.05),p16与PTEN、DNA异倍体不相关(P>0.05)。 结论: p16、CyclinD1、PTEN和DNA异倍体的异常表达共同影响了宫颈癌细胞的分裂周期,可以联合起来作为宫颈癌恶性生物学行为的观测和干预指标。

The Expression of Tumor Proliferation-related Factors in Cervical Carcinoma

Objective: To observe the expression of P16, CyclinD1, and PTEN, to determine the significance of thisexpression, and to report abnormal DNA ploidy in squamous cervical cancer. Methods: A total of 123 specimens includ-ing 82 specimens of invasive cervical carcinoma (ICC), 22 specimens of cervical intraepithelial neoplasia (CIN) and 19specimens of normal cervical (NC) tissues were analyzed by SP immunohistochemistry. Flow cytometry was used to detectthe expression of P16, CyclinD1, and PTEN as well as abnormal DNA ploidy. Results: The expression rates of P16,Cy-clinD1, PTEN, and abnormal DNA ploidy in NC, CIN, and ICC were 10.53%, 40.91%, 57.32%, and 100%; 68.18%,39.02%, 21.05%, and 50%; and 60.98%, 0%, 27.27%, and 73.17%, respectively. These results suggest that as cancerstage increases, P16 expression, CyclinD1 expression, and presence of an abnormal ploidy number increase graduallywhile PTEN expression decreased gradually. P16 expression was correlated with clinical stage, pathological grade, lymphnode metastasis and tumor size. PTEN expression was correlated with clinical stage, lymph node metastasis and tumor size.CyclinD1 expression was correlated with clinical stage and lymph node metastasis. Abnormal DNA ploidy was not corre-lated with the clinical or pathological parameters of ICC. Conclusion: The abnormal expression of P16, CycinD1, and PTEN along with abnormal DNA ploidy can influence cell cycle. These parameters can also be used in combination asmarkers for ICC diagnosis and as targets for ICC treatment.